iSpecimen Inc. (NASDAQ:ISPC – Get Free Report) was the recipient of a significant growth in short interest in October. As of October 30th, there was short interest totaling 305,211 shares, a growth of 92.3% from the October 15th total of 158,754 shares. Based on an average daily volume of 412,744 shares, the short-interest ratio is currently 0.7 days. Currently, 13.8% of the company’s shares are sold short.
Wall Street Analyst Weigh In
Separately, Weiss Ratings upgraded shares of iSpecimen from a “sell (e)” rating to a “sell (e+)” rating in a report on Thursday, October 29th. One analyst has rated the stock with a Sell rating. According to MarketBeat, the stock currently has an average rating of “Sell”.
View Our Latest Stock Report on iSpecimen
iSpecimen Stock Performance
NASDAQ ISPC opened at $0.60 on Tuesday. iSpecimen has a 52 week low of $0.57 and a 52 week high of $27.44. The stock’s 50 day moving average price is $1.05 and its two-hundred day moving average price is $4.19. The stock has a market capitalization of $1.52 million, a price-to-earnings ratio of -0.01 and a beta of 1.54.
iSpecimen (NASDAQ:ISPC – Get Free Report) last issued its quarterly earnings results on Tuesday, November 17th. The company reported ($1.03) earnings per share for the quarter. iSpecimen had a negative return on equity of 524.39% and a negative net margin of 2,445.40%. The business had revenue of $0.24 million for the quarter.
About iSpecimen
iSpecimen, Inc. operates an online marketplace that connects life-science researchers with hospitals, laboratories, biobanks and other providers of human biospecimens. Its platform is designed to help researchers find and request samples for medical and scientific research. Through its iSpecimen Marketplace, the company facilitates access to materials such as blood, tissue and other human specimens, along with associated data when available. It also supports the coordination of specimen sourcing and fulfillment between research organizations and providers.
See Also
- Five stocks we like better than iSpecimen
- Tyson Foods’ 10% Surge Puts a Breakout in Sight, But Wall Street Remains Cautious
- Microsoft’s Outage Barely Moved Its Stock, But a Bigger Risk May Be Building
- MongoDB’s Biggest Advantage May Be GitLab’s Biggest Weakness
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
Receive News & Ratings for iSpecimen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iSpecimen and related companies with MarketBeat.com's FREE daily email newsletter.
